There is a growing trend toward health care companies using technology to connect with consumers. Even big pharma is paying attention and seems determined to participate in the consumerization of health care.
I recently attended HLTH 2022 in Las Vegas. It was an inspiring gathering of thousands of health care professionals—investors, pharma, tech, hospital systems, startups, and more—joining forces to discuss the latest technologies and innovations transforming health care. Most of the technologies on display reinforced the health care industry’s focus on the consumerization of health care.
Finding and connecting directly with the consumer seems to be the direction everyone in the health care industry is headed.
The biggest surprise? Learning the traditional pharmaceutical sector is intensely seeking patient-centric solutions—a new strategy for an industry historically regulated against direct consumer relationships, marking perhaps one of the most significant shifts in our industry in the past 20 years.
What exactly does the consumerization of health care mean for pharma? Will a shift towards the consumer help bolster health equity? Will it speed drugs to market? Will consumer-facing technologies strengthen or distract from pharma’s core capabilities of discovering, developing, and commercializing therapies?
PHARMA’S SHIFTING FOCUS ON THE CONSUMER
Pharma’s interest in connecting with patients is understandable in the era of empowered consumers who are no longer content to be passive observers on their health care journey. At HLTH, the conversation centered around technologies that do just this—putting the patient first to help pharma enhance health equity, patient centricity, and personalized medicine. These terms dominated presentations and conversations.
While the patient-centric lexicon is still evolving and is often used interchangeably across different segments of health care, three indicators at HLTH reinforced pharma’s focus on sourcing patient-centric technologies:
- My company participated in a tech startup pitch competition. Of the 12 companies, ours was the only technology solution not intended for patient or practitioner use.
- On the convention floor, booth after booth of companies offered exciting and much-needed patient-centric technologies.
- The most significant indicator came from meetings with digital and innovation teams from 10 medium and large pharma companies; all but one stated the focus for 2023 is patient-centric technologies and that technologies to accelerate drug development processes were not a focus.
While this strategy will likely break down walls to patients, the question remains: Will pharma’s patient-centric tech trend distract from its core mission of speeding the availability of life-changing drugs?
A MISSION-CRITICAL PURPOSE
In my opinion, a patient-focused approach is necessary but not sufficient for pharma to fully advance health equity. The Centers for Disease Control and Prevention defines health equity as “the state in which everyone has a fair and just opportunity to attain their highest level of health.” For pharma, increasing health equity is a mission-critical purpose.
This means removing barriers related to race, color, gender, socioeconomic status, and other factors that impact equitable access to medications. Pharma is banking on consumer-based digital health solutions to help expand access to drugs and thereby improve health equity.
An equally important but non-patient-focused element of improving health equity is the ability of pharma to comprehensively study drugs in diverse patient populations. Yet, time and resource limitations make it nearly impossible for drug development teams to study all patient segments during the development process.
Innovative technologies designed to accelerate the drug development process offer a solution by creating efficiencies that allow development teams to do more with less. AI-powered technologies can accelerate the speed a pharma company moves a drug from the lab to the market, a concept known as development velocity.
Improving DV helps eliminate inefficiencies in development processes, allowing opportunities to study therapies in more diverse populations while still meeting timelines and staying within budgets. The result? More drugs delivered faster to more patients.
A MORE PATIENT-CENTRIC APPROACH TO PHARMA
Patient centricity involves making health care more about the patient and less about profit or revenue. Investment in technologies that help pharma incorporate patient input into decision-making processes highlights a change from pharma’s traditional science-only focus.
Specifically in drug development, implementing patient-centric approaches means pharma prioritizes patient and caregiver input throughout a drug’s lifecycle to better understand the drug’s impact and ensure it is meeting user needs.
Despite the increased interest and discussions around patient-centric approaches to drug development, a 2022 study suggests pharma lacks consistent and effective methods for engaging patients in research and development practices. Hence pharma’s urgent quest for technology solutions to support its patient-centric goals.
As the consumer comes into focus for pharma, there must be a balance between technologies that create efficiencies accelerating drug development and those that drive the consumerization of pharmaceuticals. The focus on the consumer cannot detract from pharma’s core mission: to develop drugs efficiently and safely.
Equal prioritization of innovations accelerating development velocity to get therapies to market faster is essential, and I believe it will also allow pharma to deliver on the trend toward the consumerization of health care.
Donna Conroy, M.S. is the Co-Founder/CEO of SciMar ONE, Inc.